Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Aug 6;12(8):e0065424.
doi: 10.1128/spectrum.00654-24. Epub 2024 Jun 25.

Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life

Marta Mejías-Trueba  1 , Alicia Gutierrez-Valencia  2   3 , Silvia Llaves-Flores  2 , Cristina Roca-Oporto  2 , Marta Herrero  2 , César Sotomayor de la Piedra  2 , Luis F Lopez-Cortes  2 , Nuria Espinosa  2
Affiliations
Observational Study

Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life

Marta Mejías-Trueba et al. Microbiol Spectr. .

Abstract

Real-life data on doravirine (DOR) in different drug combinations are limited. We evaluated the effectiveness of DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTI), mainly abacavir/lamivudine, and dual therapies in people with HIV (PWH), mostly virologically suppressed. Ambispective observational study that enrolled adults PWH who initiated a DOR-based regimen from September 2020 to February 2022 at a referral center in Spain. Participants were grouped as follows: A, received DOR plus two NRTI; B, dual therapy (DT) with DOR plus dolutegravir (DTG) or darunavir/cobicistat (DRVc); C, DOR plus ≥two antiretroviral drugs. The primary endpoints were treatment effectiveness at week 48 by intention-to-treat (ITT) and per-protocol analysis (OT). A cohort of 187 participants, 91% virologically suppressed, were analyzed after a median follow-up of 112 weeks (80-136). Group A received DOR plus abacavir/lamivudine (ABV/3TC) (n = 109) or tenofovir/emtricitabine (TFV/3TC) (n = 45). At week 48, the effectiveness of DOR plus ABV/3TC by ITT was 90.8% (CI95, 88.0-93.6), better than with TFV/FTC [73.3% (66.7-79.9); P = 0.003]. Only one virologic failure was observed. Mild adverse effects were the cause of treatment discontinuation in 7.8%, followed by switching to a single-tablet regimen. In group B, the effectiveness by ITT was 92.9% (CI95, 88.0-97.8) at week 48. No adverse effects or virologic failure were registered in this group. DOR plus two NRTI or DT have long-term effectiveness and safety as a switching option for PWH, mostly virologically suppressed. The DOR plus ABV/3TC combination has shown even better effectiveness than TFV/FTC.IMPORTANCEDOR-based regimens have shown long-term effectiveness and safety in PWH, mostly virologically suppressed. The combination of DOR plus ABV/3TC has shown even better safety and effectiveness than TFV/FTC. DOR plus two NRTI offers cost benefits compared to other regimens.

Keywords: ARV; HIV cure; treatment; viral supression.

PubMed Disclaimer

Conflict of interest statement

L.F.L.-C. has received unrestricted research funding outside the submitted work from Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare; consultancy fees and lecture fees from Gilead Sciences and ViiV Healthcare. N.E. has received fees as a consultant and speaker from ViiV Healthcare, Merck Sharp & Dohme, Gilead Sciences, and travel grants from Gilead Sciences and Merck Sharp for attending conferences. C.S., M.H. and A.G.-V. have received travel grants for attending conferences from Gilead Sciences.

References

    1. Pifeltro [package insert]. 2019. Full prescribing information of doravirine (pifeltro). Whitehouse Station, NJ: Merck & CO., Inc, Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210806s007lbl.pdf.
    1. European AIDS Clinical Society . EACS guidelines version 12. Available from: https://www.eacsociety.org/media/guidelines-12.0.pdf. Retrieved 24 Oct 2023. 24 Oct 2023
    1. Orkin C, Squires KE, Molina J-M, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. 2021. Doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) versus efavirenz/emtricitabine/TDF in treatment-naive adults with human immunodeficiency virus type 1 infection: week 96 results of the randomized, double-blind, phase 3 drive-ahead noninferiority trial. Clin Infect Dis 73:33–42. doi:10.1093/cid/ciaa822 - DOI - PMC - PubMed
    1. Molina J-M, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai M-T, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA, DRIVE-FORWARD trial group . 2020. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV 7:e16–e26. doi:10.1016/S2352-3018(19)30336-4 - DOI - PubMed
    1. Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y, Morais C, Kumar S, Sklar P, Hanna GJ, Hwang C, Greaves W, DRIVE-SHIFT Study Group . 2019. Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr 81:463–472. doi:10.1097/QAI.0000000000002056 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources